ACHIEVE Trial
The ACHIEVE Phase 3 clinical trial program evaluates orforglipron, an investigational oral nonpeptide GLP-1 receptor agonist, in adults with type 2 diabetes across a range of treatment settings.
-
Professor Francesco Giorgino
Orforglipron added to insulin glargine in adults with inadequately controlled T2D.
-
Dr Alice Y.Y. Cheng
The role of nonpeptide oral GLP-1 receptor agonists in the T2D treatment algorithm.
-
Dr Julio Rosenstock
Orforglipron compared with oral semaglutide in adults with T2D inadequately controlled on metformin.
